HBM Healthcare Investments

HBM Healthcare Investments is a publicly traded Swiss investment company based in Zug that holds a globally diversified portfolio of clinical-stage private therapies alongside listed healthcare positions. As a permanent capital vehicle rather than a closed-end fund, HBM has flexibility around hold periods and concentration, building meaningful private equity stakes in pharma, biotech, and medical device companies primarily at the clinical and commercial stages. Their public-market structure provides transparency that most private healthcare investors lack.

HBM invests at Series B, Series C, and Growth stages, deploying $5M to $25M per private investment as a participating investor in syndicates led by specialist healthcare VCs. Geographic scope is global, with strong North American and European deployment and growing exposure to Asian biotech.

Founders should treat HBM as a sophisticated late-stage syndicate partner that brings capital and capital-markets credibility rather than early-stage hands-on company building. Expect rigorous clinical, regulatory, and commercial diligence appropriate to a public-vehicle balance sheet. Engagement typically comes through co-investors and bankers running competitive private rounds at the late-clinical or pre-IPO stage.